PET100: A Promising Drug Target / Biomarker (G100131801)
PET100: A Promising Drug Target / Biomarker
PET100 is a protein that is expressed in human tissues and has been identified as a potential drug target or biomarker. PET100 is a glycoprotein that is composed of two distinct subunits, A and B. The subunit A is a monoclonal antibody (mAb) that recognizes the carcinoembryonic antigen (CEA), while the subunit B is a constant protein (CP).
Recent studies have shown that PET100 is expressed in various human tissues, including cancer cells, and has been associated with the development and progression of several types of cancer. This has led to interest in using PET100 as a potential drug target or biomarker.
PET100 has been identified as a potential drug target due to its ability to interact with several different drugs, including small molecules, antibodies, and radioactive tracers. Studies have shown that when PET100 is targeted with small molecules or antibodies, it can be inhibited or modified, leading to the inhibition of cell proliferation or the destruction of cancer cells.
One of the potential benefits of using PET100 as a drug target is its non-invasive nature. Unlike traditional cancer treatments, which often cause significant side effects, PET100-targeted treatments are designed to be administered in a non-invasive manner. This makes them a more attractive option for cancer treatments.
PET100 has also been identified as a potential biomarker for the diagnosis and prognosis of cancer. The ability to detect and measure the expression of PET100 in cancer cells has led to the development of several potential biomarkers for cancer diagnosis and treatment.
Studies have shown that the expression of PET100 is associated with the development and progression of several types of cancer, including breast, lung, and ovarian cancer. This has led to the use of PET100 as a potential biomarker for the diagnosis and prognosis of these cancers.
PET100 has also been shown to be a useful biomarker for tracking the effectiveness of cancer treatments. By measuring the expression of PET100 in cancer cells after treatment, researchers can determine the effectiveness of different treatments and identify potential areas for improvement.
In conclusion, PET100 is a protein that has been identified as a potential drug target or biomarker in several studies. Its non-invasive nature and association with cancer make it an attractive option for cancer treatments. Further research is needed to fully understand the potential of PET100 as a drug target or biomarker.
Protein Name: PET100 Cytochrome C Oxidase Chaperone
Functions: Plays an essential role in mitochondrial complex IV maturation and assembly
More Common Targets
PET117 | PFN1P8 | PGAM1P5 | PGAM1P7 | PGAM5 | PGBD4 | PGBD4P3 | PGBD4P4 | PGPEP1 | PGR-AS1 | PHACTR3-AS1 | PHB1P8 | PHB1P9 | PHC1 | PHC2 | PHEX-AS1 | PHF2P2 | PHKA2-AS1 | PHOSPHO1 | PHOSPHO2-KLHL23 | PIANP | PIGK | PIH1D2 | PIK3AP1 | PIK3R4 | PIMREG | PIN1-DT | PINK1-AS | PIR-FIGF | PITPNA-AS1 | PITPNM2-AS1 | PITRM1-AS1 | PITX1-AS1 | PIWIL2-DT | PIWIL4-AS1 | PKD1L1 | PKP4-AS1 | PLA2G12AP1 | PLA2G2E | PLA2G4B | PLAAT5 | PLAC4 | PLAGL2 | PLAT | PLAU | PLAUR | PLBD2 | PLCB2 | PLCB3 | PLCB4 | PLCD1 | PLCG1 | PLCG2 | PLCL1 | PLD1 | PLD2 | PLEC | PLEK | PLEKHA5 | PLG | PLGLB1 | PLGLB2 | PLIN1 | PLK1 | PLN | PLOD1 | PLOD2 | PLP1 | PLP2 | PLPP4 | PLPPR5 | PLPPR5-AS1 | PLRG1 | PLS1 | PLS3 | PLSCR1 | PLTP | PLUT | PLXNA1 | PLXNA2 | PLXNB1 | PLXNB3 | PLXNC1 | PMAIP1 | PMCH | PMCHL1 | PMCHL2 | PMF1-BGLAP | PML | PMM1 | PMM2 | PMP2 | PMP22 | PMS1 | PMS2 | PMS2P1 | PMS2P2 | PMS2P3 | PMS2P4 | PMS2P5